<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05013957</url>
  </required_header>
  <id_info>
    <org_study_id>NEMESIs study</org_study_id>
    <nct_id>NCT05013957</nct_id>
  </id_info>
  <brief_title>Neuroendocrine Neoplasms Methylation Based Classifier - The NEMESIs-study</brief_title>
  <acronym>NEMESIs</acronym>
  <official_title>Neuroendocrine Neoplasms Methylation Based Classifier - The NEMESIs-study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Basel, Switzerland</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Basel, Switzerland</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Neuroendocrine neoplasms (NEN) are rare tumors that mainly occur in the gastrointestinal&#xD;
      tract and the lungs. The currently available diagnostic and prognostic markers do not&#xD;
      adequately represent the diversity of these tumors. Methylation analyzes of the tumor DNA&#xD;
      represent a new, promising approach.&#xD;
&#xD;
      The aim of this project is therefore to improve the diagnostic and prognostic evaluation of&#xD;
      neuroendocrine neoplasms by means of methylation analysis of the tumor DNA. On the one hand,&#xD;
      existing tumor samples from the biobank of Basel University Hospital are evaluated, on the&#xD;
      other hand, patients who are undergoing an operation will be prospectively inquired&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 1, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2031</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2024</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Other</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Methylation-based classification of NEN samples</measure>
    <time_frame>3 years</time_frame>
    <description>NEN samples will be classified according to methylation analysis</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Neuroendocrine Tumors</condition>
  <arm_group>
    <arm_group_label>Retrospective analysis</arm_group_label>
    <description>Methylome of existing neuroendocrine tumor samples from the biobank of Basel University Hospital will be evaluated</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Prospective analysis</arm_group_label>
    <description>Methylome analysis of tumor samples of neuroendocrine tumor patients undergoing an operation or biopsy will be prospectively evaluated</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Methylation analysis</intervention_name>
    <description>Methylation analysis</description>
    <arm_group_label>Prospective analysis</arm_group_label>
    <arm_group_label>Retrospective analysis</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Neuorendocrine tumor patients&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  neuroendocrine tumor&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  insufficient amount or quality of neuroendocrine tumor sample&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>August 17, 2021</study_first_submitted>
  <study_first_submitted_qc>August 17, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 20, 2021</study_first_posted>
  <last_update_submitted>August 17, 2021</last_update_submitted>
  <last_update_submitted_qc>August 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Methyloma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Neuroendocrine Tumors</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

